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placental tissues and is the farthest upstream. The PII promoter is utilized in the ovary and in breast cancer tissues, and
it contains a cAMP response element. Promoters PI.3, PI.4,
PI.6, and PI.7 are the promoters used in extraglandular sites.
Promoter PI.4 is the primary promoter used in normal adipose tissue and is responsive to glucocorticoids and cytokines
such as IL-1␤, IL-6 and TNF␣.
The increased expression of aromatase cytochrome P450
observed in breast cancer tissues was associated with a switch
in the major promoter region utilized in gene expression. In
the normal breast cells, aromatase expression is primarily
derived by the tissue-specific promoter I.4 for transcription,
whereas expression from breast cancer patients switches from
promoter I.4 to promoter I.3 and promoter II [14]. As a result
of the use of the alternate promoter, the regulation of estrogen
biosynthesis switches from one controlled primarily by glucocorticoids and cytokines to a promoter regulated through
cAMP-mediated pathways [14]. The prostaglandin PGE2
increases intracellular cAMP levels and stimulates estrogen
biosynthesis [14], whereas other autocrine factors such as
IL-1␤ do not appear to act via PGE2 [15].
Aromatase and cyclooxygenases in breast cancer
Prostaglandin G/H endoperoxide synthase, also referred
to as cyclooxygenase (COX), is a key enzyme which catalyzes the conversion of arachidonic acid to prostaglandins.
Local production of PGE2 via the cyclooxgenase isozymes
(constitutive COX-1 isozyme and inducible COX-2 isozyme)
can influence estrogen biosynthesis and estrogen-dependent
breast cancer. This biochemical mechanism may explain
epidemiological observations of the beneficial effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on breast cancer
[16–19]. Previous studies in our laboratory suggest a relationship between CYP19 gene expression and the expression of
COX genes [20]. Gene expressions of CYP19, COX-1, and
COX-2 were performed in 20 human breast cancer specimens
and in 5 normal control breast tissue samples. A positive correlation was observed between CYP19 expression and the
greater extent of breast cancer cellularity, in agreement with
literature reports showing that aromatase levels were higher
in tumors than in normal tissue. Furthermore, a positive linear correlation was observed between COX-2 expression
breast cancer cellularity in each sample. Linear regression
analysis using a bivariate model shows a strong linear association between CYP19 expression and the sum of COX-1
and COX-2 expression. Similar correlations between CYP19
expression and COX-2 expression in breast cancer patient
specimens have been confirmed in other laboratories [21].
This significant relationship between the aromatase and
cyclooxygenase enzyme systems suggests that autocrine
and paracrine mechanisms may be involved in hormonedependent breast cancer development via growth stimulation
from local estrogen biosynthesis. In human breast stromal
cells, PGE2 acts via two G-protein coupled receptors, EP1
and EP2 receptors, to stimulate aromatase gene expression

Fig. 1. Effect of NSAIDs and COX-specific inhibitors on aromatase enzyme
activity. (A) SK-BR-3 cells were treated with indomethacin (), piroxicam
(䊉), ibuprofen (), or SC-560 (), and aromatase activity was measured
using the tritiated water-release assay. (B) SK-BR-3 cells were treated with
NS-398 (), nimesulide (), SC-58125 (), celecoxib (䊉), or niflumic acid
(), and aromatase activity was measured using the tritiated water-release
assay.

via protein kinase A and protein kinase C signaling pathways [22]. NSAIDs, COX-1 and COX-2 selective inhibitors
produce dose-dependent decreases in aromatase activity in
breast cancer tissues (Fig. 1) [23,24]. Real-time PCR analysis
of aromatase gene expression showed a significant decrease
in mRNA levels by these agents, and the effect of COX
inhibitors on aromatase expression occurs through suppression at the tissue-specific promoters PI.3, PI.4, and PII. This
significant relationship between the aromatase and cyclooxygenase enzyme systems suggests that autocrine and paracrine
mechanisms may be involved in hormone-dependent breast
cancer development via growth stimulation from local estrogen biosynthesis (Fig. 2).
Our current research focuses on pharmacological regulation of aromatase and/or cyclooxygenases by agents that can
act locally to decrease the biosynthesis of estrogen and may
provide additional therapy options for patients with hormonedependent breast cancer. Two pharmacological approaches
are being developed, one involving mRNA silencing by
selective short interfering RNAs (siRNA) molecules and the
second utilizing small molecule drug design.
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was extracted three times with an equal amount of chloroform
to extract unused substrate and further dextran-treated charcoal. After centrifugation, a 250-l aliquot containing the
product was counted in 5 ml of liquid scintillation mixture.
Results were corrected for blanks and for the cell contents
of culture flasks, and results were expressed as picomoles of
3 H O formed per hour incubation time per million live cells
2
(pmol/h/106 cells). To determine the amount of live cells in
each flask, the cells were trypsinized and analyzed using the
diphenylamine DNA assay.
RNA extraction
Fig. 2. Model of autocrine and paracrine pathways of aromatase and
cyclooxygenases in hormone-dependent breast cancer.

Materials and methods
Reagents
The synthesis of the sulfonanilide analogs is described in
our recent publication [25].
Cell culture
The MCF-7 and SK-BR-3 cell lines were obtained from
ATCC (Rockville, MD). Cell cultures were maintained in
phenol red-free custom media (MEM, Earle’s salts, 1.5×
amino acids, 2× non-essential amino acids, l-glutamine,
1.5× vitamins, Gibco BRL) supplemented with 10% fetal
bovine serum (FBS), 2 mM l-glutamine and 20 mg/l gentamycin. Fetal calf serum was heat inactivated for 30 min
in a 56 ◦ C water bath before use. Cell cultures were
grown at 37 ◦ C, in a humidified atmosphere of 5% CO2
in a Hereaus CO2 incubator. For all experiments, cells
were plated in either T-25 flasks or 100 cm2 plates and
grown to subconfluency. Before treatment, the media was
changed to a defined one containing DMEM/F12 media
(Sigma) with 1.0 mg/ml human albumin (OSU Hospital
Pharmacy), 5.0 mg/l human transferin and 5.0 mg/l bovine
insulin.
Tritiated water-release assay
Measurement of aromatase enzyme activity was based
on the tritium water-release assay [22]. Cells in T-25 flasks
or 100 cm2 plates were treated with 0.1% DMSO (control),
NSAIDs (ibuprofen, piroxicam, and indomethacin), COX-1
selective inhibitor SC-560, and COX-2 selective inhibitors
(SC-58125, NS-398, celecoxib, niflumic acid and nimesulide) at the indicated concentrations. After 24 h, the cells
were incubated for 6 h with fresh media along with 50 nM
androstenedione including 2 Ci [1␤-3 H]-androst-4-ene3,17-dione. Subsequently, the reaction mixture was removed,
and proteins were precipitated using 10% trichloroacetic acid
at 42 ◦ C for 20 min. After a brief centrifugation, the media

Total RNA was isolated using the TRIzol reagent according to the manufacturer’s protocol. Total RNA pellets were
dissolved in DNase, RNase-free water and quantitated using
a spectrophotometer. The quality of RNA samples was determined by electrophoresis through agarose gels and staining
with ethidium bromide; the 18S and 28S rRNA bands were
visualized under ultraviolet light.
cDNA synthesis
Isolated total RNA (2 g) was treated with DNase I,
Amplification grade, according to the recommended protocol
to eliminate any DNA before reverse transcription. Treated
total RNA was denatured at 65 ◦ C for 5 min in the presence of 2.5 ng/l random hexamers and 0.5 mM dNTP mix.
The samples were snap-cooled on ice and centrifuged briefly.
Complementary DNA (cDNA) was synthesized using Superscript II reverse transcriptase according to the recommended
protocol. Briefly, the reactions were conducted in the presence of 1× First-Strand Buffer and 20 mM DTT at 42 ◦ C
for 50 min and consequently inactivated at 70 ◦ C for 15 min.
The cDNA generated was used as a template in real-time PCR
reactions.
Real-time PCR
Real-time PCR was performed using the OpticonTM 2 system from MJ Research (Waltham, MA). For the CYP19 total
gene the PCR reaction mixture consisted of Taqman® Universal PCR Master Mix (Applied Biosystems), 600 nM of
each primer (Invitrogen), 250 nM Taqman probe, 18S rRNA
(Applied Biosystems, Foster City, CA), and 2.5 l of each
RT sample in a final volume of 25 l. Cycling conditions
were 50 ◦ C for 2 min and 95 ◦ C for 10 min, followed by 50
cycles at 95 ◦ C for 15 s and 60 ◦ C for 1 min. For the specific exon I promoter regions and TATA-box-binding protein
(TBP), the PCR reaction mixture consisted of DyNAmo Hot
Start SYBR Green qPCR kit (MJ Research), 600 nM of each
primer [24], and 2.5 l of each RT sample in a final volume
of 20 l. SYBR Green uses a dye that will bind to double
stranded DNA. In this methodology, the primers are carefully designed to each of the promoter regions of aromatase
exon I. Cycling conditions were 95 ◦ C for 15 min, followed
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by 50 cycles at 94 ◦ C for 10 s and 60 ◦ C for 25 s and 72 ◦ C
for 30 s.
Statistical analysis
Statistical and graphical information was determined
using GraphPad Prism software (GraphPad Software Incorporated) and Microsoft Excel (Microsoft Corporation).
Determination of IC50 values was performed using nonlinear
regression analysis. Statistically significant differences were
calculated with the two-tailed unpaired Student’s t-test and P
values reported at 95% confidence intervals.

Results
RNA interference of aromatase and
cyclooxygenase-2
Newly developed RNA interference (RNAi) technology was utilized to further probe the interactions between
aromatase and cyclooxygenases in breast cancer. RNAi
technology permits transient suppression of the levels of
endogenous proteins in mammalian cells by enhancing the
degradation of target mRNA. One RNAi approach involves
transfection of 21–23 nucleotide double-stranded, short interfering RNAs into mammalian cells. These siRNAs are
then incorporated into the RNA-inducing silencing complex
(RISC), and RISC unwinds the siRNA duplex using ATP. The
unwound, single-stranded antisense strand guides RISC to
mRNA that has a complementary sequence, and the complex
results in the endonucleolytic cleavage of the target mRNA.
Short interfering RNAs were designed to target either
human CYP19 mRNA or human COX-2 mRNA. The
designed siRNAs were transiently transfected in SK-BR3 cells, and several were effective in suppressing CYP19
mRNA and in decreasing COX-2 mRNA [23]. Two siRNA
molecules, termed siAROM and siCOX2, were chosen for
further investigations in SK-BR-3 cells. The transfection
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of siAROM resulted in suppression of CYP19 mRNA levels by greater than 90% compared with cells transfected
with a nonspecific control siRNA, termed siCTRL (Fig. 3A).
The siAROM produced little suppression of COX-2 mRNA
expression (Fig. 3B). Also shown in Fig. 3B, transfection
of siCOX2 suppressed COX-2 mRNA levels by greater than
90% compared with cells transfected with siCTRL. This
siCOX2 also resulted in suppression of CYP19 mRNA levels
by approximately 60% (Fig. 3A). Thus, the suppression of
COX-2 mRNA, which lowered levels of COX-2 enzyme and
decreased prostaglandin production, results in suppression of
CYP19 mRNA levels.
The effects of siAROM and siCOX2 on aromatase enzyme
activity in SK-BR-3 cells were also examined. The transfection of siAROM resulted in suppression of basal levels of
aromatase activity by greater than 90% compared with cells
transfected with a nonspecific control siRNA or untreated
cells (Fig. 4A). Also shown in this figure, the siCOX2 also
resulted in suppression of aromatase activity by approximately 67%. Furthermore, treatment of SK-BR-3 cells with
the combination of forskolin and dexamethasone results
in stimulation of aromatase activity, and the siAROM and
siCOX2 both significantly suppressed the induced aromatase
activity in these cells (Fig. 4B). Finally, the administration
of PGE2 to cells treated with the siRNAs results in antagonism of only the siCOX2 and restores aromatase activity to
untreated levels (Fig. 5).
Novel sulfonanilide analogs for suppression of
aromatase expression and activity
As shown in Fig. 1, different COX-2 inhibitors with similar IC50 values (concentration for 50% inhibition) for COX-2
inhibition differ significantly in their ability to suppress aromatase activity. This observation suggests differences in the
mechanisms by which these COX inhibitors modulate aromatase expression in SK-BR-3 cells. It is noteworthy that
the effect of aromatase suppression by the COX-2 selective
inhibitor NS-398 was greater than other COX-2 inhibitors,

Fig. 3. Suppression of CYP19 mRNA (A) and COX-2 mRNA (B) by siRNA molecules transfected into SK-BR-3 breast cancer cells. Each data bar represents
the mean results of three independent determinations. * P < 0.05 vs. control by unpaired t-test.
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Fig. 4. Suppression of basal aromatase activity (A) and stimulated aromatase activity (B) by siRNA molecules transfected into SK-BR-3 breast cancer cells.
Each data bar represents the mean results of three independent determinations. * P < 0.05 vs. control by unpaired t-test.

Fig. 5. Effect of PGE2 on suppression of aromatase activity by siRNAs.

even though NS-398 has weak COX-2 inhibitory activity.
To determine whether the modulation of aromatase expression by NS-398 required the inhibition of COX-2 enzyme
activity, we designed and synthesized NS-398 analogs with
no COX-2 inhibitory activity (Fig. 6) [25]. Introduction of a

Fig. 6. Synthetic novel sulfonanilides.

methyl group at the N atom of the sulfonamide group to the
COX-2 inhibitor nimesulide resulted in no COX-2 inhibitory
activity [26]. This structural modification was utilized in our
drug design. The nitrate group at the 4 position of NS-398
was retained and modifications of the sulfonamide and of
the 2 position alkyl group were made to generate the new
compounds [25].
To investigate whether these compounds decrease aromatase activity in breast cancer cells, we performed a 1 M
bioassay in SK-BR-3 breast cancer cells, and most compounds significantly decreased aromatase activity (Fig. 7).
In an effort to discriminate among compounds in this library,
dose response studies of the active compounds were performed, and the resulting IC50 values of the compounds
ranged from approximately 0.20 to 6.00 M. Our results

Fig. 7. Suppression of aromatase activity in SK-BR-3 breast cancer cells.
SK-BR-3 cells were treated with indicated compounds (1 M). Aromatase
activity was measured as described in Section 2. The results were normalized
against a control treatment with vehicle. The value of 100% is equal to
0.03 pmol/h/106 cells. Each data bar represents the mean results of three
independent determinations. * P < 0.05 vs. control by unpaired t-test.
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Fig. 8. Effect of NS-398 derivatives on PGE2 production of MDA-MB231 cells. Cells were treated for 24 h with the indicated agents at 25 M.
Results are expressed as means of the concentration of PGE2 produced per
microgram protein ± S.E.M., * P < 0.05 vs. control by unpaired t-test (n = 6).

suggest that the length of the group on position 2 of the
compounds is important for the suppression of aromatase
activity. Compounds containing a methoxy (16 and 25) or an
isopropyloxy (10 and 19), which are relatively short, have
low ability to suppress aromatase activity. Extremely long
chain substituents (15, 24, 14 and 23) have reduced activity
as well, which may also be due to the poor solubility of the
compounds. All the N-methyl compounds exhibited better
activity than their corresponding unsubstituted compounds
with the exception of compounds 23 and 24. One possible
explanation is the pKa value of the reagents.
The production of PGE2 was measured in cells treated
with NS-398 and the novel sulfonanilide derivatives. NS-398,
compound 12 and 13 resulted in a significantly decrease in
PGE2 production, whereas compounds 17, 20, 21 and 22 did
not show any inhibitory activity (Fig. 8) [25]. This is consistent with our design approach that the introduction of a
methyl group in to the N atom of the sulfonamide group
results in analogs that cannot be deprotonated and thus loses
COX-2 inhibitory activity. In addition, compound 11 did not
show any COX-2 inhibitory activity, and compound 11 has
one carbon longer side chain comparing with NS-398. This
result suggests that the size of the side chain is very important for the COX-2 inhibitory activity and that this extension
affects the binding of the compound with COX-2 and results
in no COX-2 inhibitory activity.
Analysis of total CYP19 mRNA transcripts was performed using real-time PCR in order to determine whether
the decrease in aromatase activity by NS-398 in SK-BR-3
cells was due to a down-regulation of aromatase expression
at transcriptional level. SK-BR-3 cells were treated with NS398, compound 17, 13 and 22 for 24 h at concentrations at
25 M. Total RNA was extracted at 24 h, and CYP19 transcript levels were compared to control (vehicle) treatment.
All four compounds significantly decreased CYP19 gene
expression in SK-BR-3 cells relative to the control (Fig. 9).
No effect on the expression level of the housekeeping 18S
rRNA was observed with any of the compounds. Compounds
17 and 22, which do not show COX-2 inhibitory activity,

Fig. 9. Real-time RT-PCR analysis of CYP19 mRNA expression in SK-BR-3
cells. Cells were treated for 24 h with the indicated agents at 25 M, and total
RNA was isolated. Results are expressed as means of CYP19 (normalized
to 18S rRNA) ± S.E.M., * P < 0.05 vs. control by unpaired t-test (n = 9).

decreased aromatase expression at similar levels. This suggests that the compounds interfere with pathways affecting
aromatase expression in breast cancer cells that do not involve
prostaglandins and COX enzyme activities. Similar results
on CYP19 gene expression and aromatase activity have been
observed in MCF-7 human breast cancer cell cultures and in
primary cultures of isolated breast fibroblasts.

Conclusions
Local regulation of aromatase by both endogenous factors as well as exogenous medicinal agents will influence
the levels of estrogen available for breast cancer growth.
The prostaglandin PGE2 increases intracellular cAMP levels
and stimulates estrogen biosynthesis, and previous studies
in our laboratories have shown a strong linear association
between aromatase (CYP19) expression and expression of
the cyclooxygenases (COX-1 and COX-2) in breast cancer
specimens. Using selective pharmacological agents, dosedependent decreases in aromatase activity were observed
following treatment with NSAIDs, COX-1 selective inhibitor,
and COX-2 selective inhibitors. Real-time PCR analysis of
aromatase gene expression showed a significant decrease in
CYP19 mRNA levels in treated cells when compared to vehicle control. These results suggest that the effect of COX
inhibitors on aromatase occurs at the transcriptional level.
Investigations using RNA interference technology confirmed the interactions between aromatase and cyclooxygenases in breast cancer. Short interfering RNAs were designed
against either human CYP19 mRNA or human COX-2
mRNA. Treatment of breast cancer cells with siAROM
suppressed CYP19 mRNA and aromatase enzyme activity.
Treatment with stCOX2 downregulated the expression of
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COX-2 mRNA; furthermore, the siCOX-2-mediated suppression of COX-2 also resulted in suppression of aromatase
mRNA. Finally, the administration of PGE2 to cells treated
with the siRNAs results in antagonism of only the siCOX2
and restores aromatase activity to untreated levels.
The small molecule drug design approach focused on
the synthesis and biological evaluation of a novel series
of sulfonanilide analogs derived from the COX-2 selective
inhibitors. The compounds suppressed aromatase enzyme
activity in SK-BR-3 breast cancer cells in a dose-dependent
manner, and structure activity analysis did not find a correlation between aromatase suppression and COX inhibition.
Real-time PCR analysis demonstrated that the sulfonanilide
analogs decrease aromatase gene transcription in breast cells.
Thus, these results suggest that the novel sulfonanilides
targeting aromatase expression may be valuable tools for
selective regulation of aromatase in breast cancer.
Thus, the regulation of aromatase and cyclooxygenases
in breast cancer involves complex autocrine and paracrine
interactions, resulting in significant consequences on the
pathogenesis of hormone-dependent breast cancer via growth
stimulation from local estrogen biosynthesis (Fig. 2). Higher
levels of COX-2 expression and COX-2 enzyme activity could
result in higher levels of PGE2 , which in turn could increase
CYP19 expression through increases in intracellular cAMP
levels and activation of promoter 1.3 and promoter II. Thus,
the breast cancer tissue microenvironment can influence the
extent of estrogen biosynthesis and metabolism, resulting in
altered levels of hormonally active estrogens and therefore
influencing breast tumor development and growth. Furthermore, siRNAs and novel sulfonanilides targeting aromatase
expression may be valuable tools for selective regulation of
aromatase in breast cancer.
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